We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
-4.74%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$592M
AUM Growth
+$20.8M
Cap. Flow
+$57.7M
Cap. Flow %
9.74%
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
2
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$48.9M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$8.78M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
1
Biogen
BIIB
$30B
$149M 25.16%
643,000
– –
INVA icon
2
Innoviva
INVA
$1.55B
$119M 20.14%
7,277,000
– –
IRWD icon
3
Ironwood Pharmaceuticals
IRWD
$696M
$107M 18.04%
16,390,000
– –
GILD icon
4
Gilead Sciences
GILD
$162B
$75.7M 12.78%
1,103,282
– –
CYTK icon
5
Cytokinetics
CYTK
$10.5B
$60.1M 10.15%
1,110,000
+810,000
+270% +$48.9M
NBIX icon
6
Neurocrine Biosciences
NBIX
$16.8B
$56.5M 9.54%
410,483
+64,057
+18% +$8.78M
AMRN
7
Amarin Corp
AMRN
$298M
$17.1M 2.89%
1,242,531
– –
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$2.28B
$6.76M 1.14%
1,094,168
– –
VOR icon
9
Vor Biopharma
VOR
$1.15B
$618K 0.1%
30,900
– –
RGLS
10
DELISTED
Regulus Therapeutics
RGLS
$331K 0.06%
185,183
– –

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Sarissa Capital Management held 10 positions worth $592M, up 3.6% from $572M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management deployed $57.7M of net new capital in Q2 2024, adding to 2 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Sarissa Capital Management added most to Cytokinetics in Q2 2024, an estimated $48.9M increase.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $592M portfolio in Q2 2024.
  • Sarissa Capital Management opened 0 new positions and closed 0 in Q2 2024.
  • Sarissa Capital Management's portfolio value rose 3.6% quarter-over-quarter to $592M.

Based on Sarissa Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.